Education
About Us
Working with TipRanks
Follow Us
Advaxis (ADXS)
OTHER OTC:ADXS
ADXS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $0.80
Previous CloseN/A
Volume3.00
Average Volume (3M)269.00
Market Cap
$1.42M
Enterprise ValueN/A
Total Cash (Recent Filing)$4.88M
Total Debt (Recent Filing)$8.32M
Price to Earnings (P/E)―
Beta-2.69
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding42,633,400
10 Day Avg. Volume287
30 Day Avg. Volume269
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Advaxis News
ADXS FAQ
What was Advaxis’s price range in the past 12 months?
Advaxis lowest stock price was $0.02 and its highest was $0.80 in the past 12 months.
What is Advaxis’s market cap?
Advaxis’s market cap is $1.42M.
When is Advaxis’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Advaxis’s earnings last quarter?
Currently, no data Available
Is Advaxis overvalued?
According to Wall Street analysts Advaxis’s price is currently Overvalued.
Does Advaxis pay dividends?
Advaxis does not currently pay dividends.
What is Advaxis’s EPS estimate?
Advaxis’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Advaxis have?
Advaxis has 42,633,400 shares outstanding.
What happened to Advaxis’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Advaxis?
Currently, no hedge funds are holding shares in ADXS
Company Description
Advaxis
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Advaxis (ADXS) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Salarius Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Protagenic Therapeutics
―
ZyVersa Therapeutics
―
Ownership Overview
58.95% Insiders
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---